{"allTrials": {"@totalCount": "6", "@xmlns": "http://www.67bricks.com/isrctn", "fullTrial": [{"trial": {"@lastUpdated": "2010-03-31T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2010-03-25T00:00:00.000Z", "#text": "31673586"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Comparing the after-use sensation and safety of long acting (LA) carteolol 2 % versus timolol LA 0.5 % in simple intra-ocular hypertension and glaucoma", "scientificTitle": "Randomised, parallel-group, multicentre study to evaluate the after-use sensation and safety of carteolol LA 2% versus timolol LA 0.5% in simple intra-ocular hypertension and glaucoma", "acronym": "Carteolol", "studyHypothesis": "In this study the hypothesis will be tested that a 3-month treatment with Carteolol is superior\nto a 3-month treatment with Timolol in the subjective tolerance (ocular discomfort) upon\ninstillation.\nOcular hypertension or Primary Open Angle Glaucoma (POAG) (superiority design)", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Evaluation of the subjective tolerance upon instillation (rate of patients experiencing symptoms of discomfort), graded as very good, good, bad or very bad, measured at baseline, 1 and 3 months", "secondaryOutcome": "1. Assessment of each of the symptoms of the Glaucoma Symptom \nScale [15] (Yes/ No): burning/smarting/stinging, tearing, dryness, itching, soreness/tiredness, feeling of something in the eye, blurry/dim vision, hard to see in daylight, hard to see in dark places and halos around the light (for those who report a given symptom, a bothersome scale will be used: very, somewhat, a little, not at all) \n2. Slit lamp examination (examination of conjunctiva, cornea, iris, lens,  anterior chamber), performed at baseline, 1 and 3 months\n3. Tear-film-break-up-time-test (BUT-test; sec), performed at baseline, 1 and 3 months \n4. Fluorescein staining of the cornea, performed at baseline, 1 and 3 months \n5. Van Bijsterveld test (Lissamine green), performed at baseline, 1 and 3 months \n6. IOP measured at 12 PM (+/- 30mn), measured at baseline, 1 and 3 months\n7. Assessment of Visual acuity and visual field, measured at baseline (if no visual field performed during the previous 3 months) and at 3 months\n8. Fundoscopy, performed at baseline, 1 and 3 months \n9. Adverse events, reported at 1 and 3 months \n10. Compliance, reported at 1 and 3 months", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "1. Belgium (Lead Centre): Ethics Committee of UZ Leuven (KUL) approved on the 10th of April 2008 (ref: ML 4750) \n2. Czech Republic: Local ethics committee (Eticke Komise) approved on the 17th of January 2008 (refs: protocol UtCIV; approval no. 1743107S-MEK)\n3. France: Local ethics committee (Comit\u00e9 de protection des personnes Sud Est 6) approved on the 2nd of November 2007 (ref: AU 714) \n4. Poland: Local ethics committee (Komisja Bioethyczna) approved on the 6th of January 2007 (ref: KB-517/2007) \n5. Portugal: National Ethics Committee for Clinical Investigation (CEIC) approved on the 19th of May 2008 (ref: 0804AU135)"}, "externalRefs": {"doi": "10.1186/ISRCTN31673586", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "#529"}, "trialDesign": {"studyDesign": "Investigator-masked parallel group randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2007-12-11T00:00:00.000Z", "overallEndDate": "2009-08-10T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Belgium", "Czech Republic", "France", "Poland", "Portugal"]}, "trialCentres": {"trialCentre": {"@id": "f89e3e57-a8e0-4e87-8cbe-9e5cea199c15", "name": "CHU de Clermont Ferrand \u0096 Service", "address": null, "city": "Cermont Ferrand", "state": null, "country": "France", "zip": "63000"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Adult patients, men or women\n2. Suffering from unilateral or bilateral ocular hypertension or POAG\n3. Intraocular Pressure (IOP) controlled with beta-blocker monotherapy (IOP < 21mmHg and\nvisual field stable)\n4. Written informed consent", "ageRange": "Adult", "gender": "Both", "targetEnrolment": "194", "totalFinalEnrolment": null, "totalTarget": "194", "exclusion": "1. Age < 18 years\n2. IOP not controlled with beta-blocker monotherapy\n3. Angle closure, congenital and secondary glaucoma\n4. Any pathology contraindicating an IOP measurement\n5. Any intraocular infection or inflammation, ocular trauma, ocular surgery or laser trabeculoplasty within the previous 3 months\n6. Previous intolerance to carteolol or timolol, or to any other ingredients of\nthe tested products\n7. Beta-blocker contraindications\n8. Ocular corticosteroids\n9. Contact lens wearers\n10. Severe systemic or ocular disease\n11. Hypotension\n12. Drug, alcohol abuse\n13. Involvement in the last 30 days in any other investigational drug study\n14. Expected change in treatment of concomitant disease\n15. Patients with a history of recurrent ocular herpes and/or recurrent uveitis\n16. Change in ocular treatment within the last month\n17. Patients treated with other topical ocular treatment within the last month \n18. Pregnant or lactating women\n19. Women of child-bearing potential considering becoming pregnant during the course of the study and those not taking precautions to avoid pregnancy\n20. Patients for whom, in the physician's opinion, any of the protocol\nprocedures may pose a special risk not outweighed by the potential benefits of participating in the study\n21. Patients who are unlikely to comply with the study protocol or who are likely to be moving and lost to follow up in the study period\n22. Patients with neurotic, psychiatric disorders or suicidal tendencies", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2007-12-11T00:00:00.000Z", "recruitmentEnd": "2009-08-10T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Unilateral or bilateral ocular hypertension; Primary Open Angle Glaucoma (POAG)", "diseaseClass1": "Eye Diseases", "diseaseClass2": "Glaucoma"}}, "interventions": {"intervention": {"description": "Written informed consent was obtained at baseline visit 1 (day 0). Eligibility was determined by reviewing medical history, recording of concomitant medication, external eye examination (signs of inflammation on eye lids, lid closure, lid motility, bulbar motility, conjunctival injection), and a check of inclusion and exclusion criteria. \nEligible patients were randomised to receive either\n1. Carteolol LA 2%: Daily, 1 drop at 8 AM in the eye(s) to be treated over 3 months\n2. Timolol LA 0.5%: Daily, 1 drop at 8 AM in the eye(s) to be treated over 3 months\nPatients received the appropriate medication and diary card. \n\nFollow up visits were carried out on days 30 and 90 (\u00b1 3 days). Further medication and diary cards were distributed on day 30 only. Used and unused bottles and diary cards were collected at both visits. Patients were not followed up beyond the end of the intervention period.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder19553-0", "contactId": "Contact57553_19553", "sponsorId": "Sponsor56146"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact57553_19553", "title": "Prof", "forename": "Fr\u00e9deric", "surname": "Chiambaretta", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "CHU de Clermont Ferrand \u0096 Service\nd\u0092Opthalmologie\nHopital St. Jaques\n3 place Henri Dunant, BP 69", "city": "Cermont Ferrand", "country": "France", "zip": "63000", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor56146", "organisation": "Dr. Mann Pharma GmbH, Bausch & Lomb Inc. (Germany)", "website": null, "sponsorType": "Industry", "contactDetails": {"address": "c/o Gabriele Brenger\nBrunsb\u00fctteler Damm 165-173", "city": "Berlin", "country": "Germany", "zip": "13581", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.474776.1", "rorId": "https://ror.org/049ncrn81"}, "funder": {"@id": "Funder19553-0", "name": "Bausch & Lomb GmbH (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2010-03-31T00:00:00.000Z", "@version": "22", "isrctn": {"@dateAssigned": "2010-03-25T00:00:00.000Z", "#text": "03110798"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Comparing the Efficacy and Safety of Indomethacin 0.1% Eyedrops versus Ketorolac 0.5% Eyedrops in Ocular Inflammation After Cataract Surgery", "scientificTitle": "A Multicentre, Investigator-Masked, Parallel\u0096Group, Randomized, Study of the Efficacy and Safety of Indomethacin 0.1% Eyedrops Compared with Ketorolac 0.5% Eyedrops in Ocular Inflammation After Cataract Surgery", "acronym": "Indocollyr Study", "studyHypothesis": "A treatment with indomethacin 0.1% is non-inferior to a treatment with ketorolac 0.5% in the prevention of ocular inflammation following cataract surgery.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "The primary efficacy endpoint is aqueous flare, measured with an LFM, at Day 1 and Day 7 after cataract surgery", "secondaryOutcome": "1. Aqueous flare, measured with an LFM, at Day 30 and Day 90 after cataract surgery\n2. Change from baseline in retinal thickness measured with an Optical Coherence Tomograph at Day 30 and Day 90\n3. Anterior chamber flare and cells, as well as conjunctival hyperaemia and perikeratic circle, measured through slit lamp examinations\nPost surgical pain/discomfort immediately after surgery (Day 0) and 24 hours after surgery (Day 1)\n4. Change from baseline in the appearance of the macula and the rest of the retina, assessed through dilated, indirect funduscopy at Day 30 and Day 90\n5. Use of concomitant medications to treat inflammation related to cataract surgery at each visit\n\nThe safety endpoints include the following:\n6. Corneal epithelial erosions at Day 7 and Day 30 measured with fluorescein strips and a cobalt filter on a slit lamp\n7. Subjective tolerance to study drug upon instillation at Day 0 (prior to surgery), Day 7, and retrospective evaluation at Day 30\n8. Best-corrected distance visual acuity (BCDVA) at Day 7, Day 30, and Day 90\n9. Change from baseline in IOP at Day 7, Day 30, and Day 90\n10. Adverse Events", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "1. France (Lead Centre): Local Ethics Committee (Comit\u00e9 de Protection des Personnes [CPP] Tours, Ouest-1) approved on the 8th of February 2008 (ref: 2007-004686-18)\n2. Poland: Local Ethics Committee (Komisja Bioetyczna, Akademia Medyczna) approved on the 31st of March 2008 (ref: KE-0254/58/2008)\n3. Portugal: Local Ethics Committee (Comissao de Etica para a Investigacao Cl\u00ednica [CEIC], Parque da Sa\u00fada de Lisboa) approved on the 14th of April 2008 (ref: CEIC 07128BU598)\n4. Germany: Local Ethics Committee (\u00c4rztekammer des Saarlandes, Ethikkommission) approved on the 25th of September 2008 (ref: Sn 148/08)\nPotential subjects who meet  eligibility requirements will be scheduled for 6 study visits over a period of approximately  90 days. Subjects who meet eligibility requirements will be randomized (1:1) to receive test  (indomethacin 0.1%) or active-control (ketorolac 0.5%) in the study eye. Study eyes will  receive 1 drop of study drug, four times daily, for 3 weeks."}, "externalRefs": {"doi": "10.1186/ISRCTN03110798", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "# 539"}, "trialDesign": {"studyDesign": "Multicentre investigator blinded randomised active controlled parallel group trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-04-08T00:00:00.000Z", "overallEndDate": "2009-09-17T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["France", "Germany", "Poland", "Portugal"]}, "trialCentres": {"trialCentre": {"@id": "f9d15754-1001-430b-ac56-4c14150765c0", "name": "Service d\u0092Ophthalmologie", "address": null, "city": "Nantes", "state": null, "country": "France", "zip": "44093"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Subjects must be of legal age (at least 18) and have full legal capacity to volunteer.\n2. Subjects must read, understand, and sign the Institutional Review Board/Independent\nEthics Committee approved Informed Consent Form.\n3. Subjects must be planning to undergo cataract surgery on one eye by\nphacoemulsification with posterior chamber intraocular lens, using topical anaesthesia.\n4. Subjects must have a preoperative flare \u2264 15 ph/ms, measured with a laser flare meter\n(LFM) without pharmacological pupil dilation, within the 2 months preoperatively.\n5. Subjects who are women of childbearing potential must have a negative urine\npregnancy test at baseline.\n6. Subjects who are able and willing to comply with all treatment and follow-up\nprocedures", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "120", "totalFinalEnrolment": null, "totalTarget": "120", "exclusion": "1. Subjects who have an inflammatory and/or infectious pathology of the eye and its adnexa\n2. Subjects who have a history of postoperative intraocular infection in the fellow eye\n3. Subjects who have glaucoma in the study eye\n4. Subjects who have post-traumatic cataract in the study eye\n5. Subjects who have exfoliative syndrome\n6. Subjects who have diabetes\n7. Subjects who have an active peptic ulcer\n8. Subjects who have severe hepatocellular impairment or severe renal impairment\n9. Subjects who have a history of uveitis\n10. Subjects who have any progressive pathology requiring the use of topical or systemic anti-inflammatory or anti-infectious agents\n11. Subjects who take acetylsalicylic acid at doses > 100 mg daily and cannot discontinue usage during the study\n12. Subjects who have a history of asthma linked to acetylsalicylic acid or other nonsteroidal anti-inflammatory (NSAI) drug administration\n13. Subjects with immunodepression\n14. Subjects with a history of intolerance to the study drug or to any NSAI drug\n15. Subjects who are monocular for any reason other than cataract\n16. Subjects who are treated with local or systemic anti-inflammatory drugs within 10 days prior to inclusion\n17. In the case of cataract surgery on the 2nd eye, if the subject was already included in the study for the 1st eye, the 2nd eye cannot be considered another study eye.\n18. Subjects who have surgery planned to occur during the course of the study other than cataract surgery on the study eye or cataract surgery on the fellow eye. If cataract surgery is planned to occur for the fellow eye before Visit 5 (Day 30, \u00b13 days) is completed, the subject must be excluded.\n19. Women who are pregnant or breastfeeding\n20. Women who are sexually active and who do not fall into one of the following\ncategories:\n20.1. Post menopausal\n20.2. Surgically sterile\n20.3. Using one of the following birth control methods throughout the duration of the study:\n20.3.1. Intrauterine device (>14 days)\n20.3.2. Barrier method (condom or diaphragm) with spermicide (>14 days)\n20.3.3. Hormonal contraception (same dose and same formulation for at least six months)\nSecondary criteria for exclusion from the efficacy analysis include perioperative complications (i.e., vitreous loss, complicated capsular rupture, and anterior chamber\nintraocular lens) which will also be considered adverse events (AEs)", "patientInfoSheet": "Not available", "recruitmentStart": "2008-04-08T00:00:00.000Z", "recruitmentEnd": "2009-09-17T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Cataract; surgery; phacoemulsification", "diseaseClass1": "Eye Diseases", "diseaseClass2": "Cataract"}}, "interventions": {"intervention": {"description": "Potential subjects who meet eligibility requirements will be scheduled for 6 study visits over a period of approximately  90 days. Subjects will be randomized (1:1) to receive test (indomethacin 0.1%) or active-control (ketorolac 0.5%) in the study eye. Study eyes will receive 1 drop of study drug, four times daily, for 3 weeks.\n\nThe test article is commercially available with different brand names in the countries where the study takes place. It is manufactured by Bausch & Lomb, Chauvin, Montpellier, France and contains indomethacin ophthalmic solution 0.1%, preserved with thiomersal (10 mg/100 ml).\nThe active control is commercially available Acular, marketed by Allergan Incorporated in France. Acular contains ketorolac tromethamine 0.5% and is preserved with benzalkonium chloride 0.01%.", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Phase IV", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder19554-0", "contactId": "Contact57554_19554", "sponsorId": "Sponsor56147"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact57554_19554", "title": "Prof", "forename": "Michel", "surname": "Weber", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Service d\u0092Ophthalmologie\nHotel Dieu CHU de Nantes\n1 place Alexis Ricordeau", "city": "Nantes", "country": "France", "zip": "44093", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor56147", "organisation": "Dr. Mann Pharma GmbH, Bausch & Lomb Inc. (Germany)", "website": null, "sponsorType": "Industry", "contactDetails": {"address": "c/o Gabriele Brenger\nBrunsb\u00fctteler Damm 165-173", "city": "Berlin", "country": "Germany", "zip": "13581", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.474776.1", "rorId": "https://ror.org/049ncrn81"}, "funder": {"@id": "Funder19554-0", "name": "Bausch & Lomb GmbH (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2010-03-31T00:00:00.000Z", "@version": "21", "isrctn": {"@dateAssigned": "2009-02-19T00:00:00.000Z", "#text": "88145753"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Intrathecal steroids for intractable postherpetic neuralgia", "scientificTitle": "Intrathecal steroids for intractable postherpetic neuralgia: a randomised controlled trial", "acronym": "STIP", "studyHypothesis": "Intrathecal administration of methylprednisolone with lidocaine is more effective than lidocaine alone in the reduction of pain in postherpetic neuralgia (PHN).", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Global pain relief at 1-year follow-up.", "secondaryOutcome": "1. Global pain relief at the end of treatment and after 4 weeks, 8 weeks, 6 months and 2 years follow-up \n2. Reduction of VAS scores for global, burning and lancinating pain, and allodynia at the end of treatment and after 4 weeks, 8 weeks, 6 months, 1 year and 2 years follow-up \n3. Reduction of areas of pain and allodynia at the end of treatment and after 4 weeks, 8 weeks, 6 months, 1 year and 2 years follow-up \n4. Reduction in mean number of paracetamol tablets consumed per week at the end of treatment and after 4 weeks follow-up \n5. Reduction in mean percentage of the maximal dose of NSAIDs used per week at the end of treatment and after 4 weeks follow-up \n6. Reduction in the percentage of the initial dose(s) of PHN medication at the end of treatment and after 4 weeks follow-up \n7. Euroqol EQ-5D scores just before treatment and at 4 weeks, 8 weeks, 6 months, 1 year and 2 year follow-up visits", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "To be submitted as of 11/11/2008"}, "externalRefs": {"doi": "10.1186/ISRCTN88145753", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "N/A"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2008-12-01T00:00:00.000Z", "overallEndDate": "2010-12-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "39573963-49db-4106-9ab6-a4f9f09f5593", "name": "University Medical Centre Utrecht", "address": null, "city": "Utrecht", "state": null, "country": "Netherlands", "zip": "3508 GA"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Outpatient, male or female, aged 18 years or older\n2. History of PHN for at least 6 months after onset of the vesicular eruption\n3. Global pain intensity due to PHN must be at least 40 mm on 100 mm Visual Analogue Scale (VAS) for the last 24 hours despite conventional therapies, as recorded at Visit 1\n4. The PHN must be restricted to the dermatomes involved in the original eruption of herpes zoster\n5. Patient does not use concomitant medication for PHN, or is using concomitant PHN medication on a stable dose for at least 4 weeks prior to randomisation\n6. Patients must be willing and able to give informed consent", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "42", "totalFinalEnrolment": null, "totalTarget": "42", "exclusion": "1. PHN in regions innervated by the trigeminal nerve\n2. Previous neurolytic or neurosurgical treatment for PHN (radiofrequency neuroablation [RF] treatment of the dorsal root ganglion is allowed)\n3. Patients who have other pain, which could confound the assessment of the neuropathic pain due to PHN\n4. Patients with polyneuropathy or other severe neurologic disease (e.g., multiple sclerosis)\n5. Patients with diseases accompanied with a severe immunocompromised state (e.g., during chemotherapy, AIDS; HIV is not an exclusion criterion)\n6. Use of coumarin anticoagulants\n7. Contra-indications for spinal anaesthesia\n8. Contra-indications for oral non-steroidal anti-inflammatory drug (NSAID) use\n9. Satisfactory pain relief with conventional treatment (including at least one trycyclic antidepressant and at least one anti-epileptic)\n10. Adjustments in concomitant PHN medication during the past 4 weeks\n11. Previous spinal anaesthesia with steroids for PHN\n12. Skin conditions in the area affected by the neuralgia that could alter sensation\n13. Clinically significant psychiatric diagnoses, in particular depression, that would impair their reliable participation in this trial\n14. Body Mass Index (BMI) >35 kg/m^2\n15. Woman of childbearing potential who is not willing or unable to take adequate birth control measures during the study and for at least 6 months after the last injection\n16. Pregnant patients and women who are lactating\n17. Problems with communication (language, deafness, aphasia)", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2008-12-01T00:00:00.000Z", "recruitmentEnd": "2010-12-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Postherpetic neuralgia", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Zoster [herpes zoster]"}}, "interventions": {"intervention": {"description": "Administration of 60 mg lidocaine (intrathecal) with or without 60 mg methylprednisolone (intrathecal).", "interventionType": "Other", "pharmaceuticalStudyTypes": null, "phase": "Not Applicable", "drugNames": null}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder18265-0", "contactId": "Contact56253_18265", "sponsorId": "Sponsor54822"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact56253_18265", "title": "Dr", "forename": "A J M", "surname": "van Wijck", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "University Medical Centre Utrecht\nPostbus 85500", "city": "Utrecht", "country": "Netherlands", "zip": "3508 GA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54822", "organisation": "University Medical Centre Utrecht (UMCU), Department of Perioperative Care and First Aid (DPenS) (Netherlands)", "website": "http://www.umcutrecht.nl", "sponsorType": "University/education", "contactDetails": {"address": "Postbus 85500", "city": "Utrecht", "country": "Netherlands", "zip": "3508 GA", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.5477.1", "rorId": "https://ror.org/04pp8hn57"}, "funder": {"@id": "Funder18265-0", "name": "University Medical Centre Utrecht (UMCU), Department of Perioperative Care and First Aid (DPenS) (Netherlands)", "fundRef": null}}, {"trial": {"@lastUpdated": "2010-03-31T00:00:00.000Z", "@version": "24", "isrctn": {"@dateAssigned": "2008-07-10T00:00:00.000Z", "#text": "69881892"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Aerosolised liposomal cyclosporin A (L-CsA) versus placebo in the treatment of bronchiolitis obliterans (BO) in allogeneic haematopoietic stem cell transplant (HSCT) patients", "scientificTitle": "A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal cyclosporin A (L-CsA) versus placebo in the treatment of bronchiolitis obliterans (BO) in allogeneic haematopoietic stem cell transplant (HSCT) patients", "acronym": "L-CsA-HSCT", "studyHypothesis": "To established an investigational medicinal product (IMP) dosage with the most favourable risk-benefit ratio for the prevention of bronchiolitis obliterans (BO) in allogeneic haematopoietic stem cell transplant (HSCT) patients.\n\nPlease note that as of 31/07/2008 the sponsor details of this trial changed to PARI Pharma GmbH (Germany). The previous sponsor was Chiltern International (Germany). \n\nAs of 12/05/2009 this trial is on hold. The anticipated start and end dates have been amended; the initial trial dates were:\nAnticipated start date: 01/11/2008\nAnticipated end date: 01/01/2011", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "To establish an IMP dosage with the most favourable risk-benefit ratio for the prevention of BO in HSCT patients.", "secondaryOutcome": "1. To compare efficacy and safety data from two different L-CsA doses versus placebo\n2. To evaluate investigational medicinal product (IMP) pharmacokinetic (PK) data in bronchoalveolar lavage (BAL) and in whole blood samples", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Ethics approval pending as of 12/05/2009."}, "externalRefs": {"doi": "10.1186/ISRCTN69881892", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "CLP 12011.202"}, "trialDesign": {"studyDesign": "A phase II, multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-finding clinical trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Hospital"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": "Stopped", "reasonAbandoned": "Lack of funding/sponsorship", "overallStartDate": "2010-03-01T00:00:00.000Z", "overallEndDate": "2012-12-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": ["Austria", "Belgium", "Denmark", "France", "Germany", "Switzerland", "United Kingdom"]}, "trialCentres": {"trialCentre": {"@id": "6fc2a828-6e95-4676-b6fa-04f6af07a196", "name": "Clinical Trial Manager", "address": null, "city": "Munich", "state": null, "country": "Germany", "zip": "81369"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "1. Signed informed consent provided prior to any screening procedure  \n2. Male or female, 12 years or older \n3. Capable of self-administrating medications\n4. Capable of understanding the purpose and risk of the study\n5. Received an allogeneic haematopoietic stem cell transplantation\n6. Has a diagnosis of bronchiolitis obliterans of grade 1, 2 or 3 based on forced expiratory volume in one second (FEV1) values according to protocol within one week prior to first investigational medicinal product administration (IMP)\n7. Obtained a FEV1 value immediately before HSCT\n8. Received within one week prior to first IMP administration the following immunosuppressive treatment and dosages for graft-versus-host-disease (GVHD) including bronchiolitis obliterans:\n8.1. Tacrolimus 0.1 to 0.2 mg/kg/day adjusted to a target trough serum level (C0) of 5 to 15 \u00b5g/L\n8.2. Prednisone 1 to 1.5 mg/kg/day for 2 to 6 weeks\n9. Female patients with child bearing potential must have a negative serum pregnancy test within 3 days prior to screening. Both women and men must agree to use a medically-acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment. Acceptable methods of contraception include intra-uterine device (IUD), oral contraceptive, subdermal implant and double barrier (condom with a contraceptive sponge or contraceptive suppository)\n10. Estimated life expectancy greater than 6 months", "ageRange": "Other", "gender": "Both", "targetEnrolment": "60", "totalFinalEnrolment": null, "totalTarget": "60", "exclusion": "1. Has an active invasive bacterial, viral or fungal infection within one week prior to first IMP administration\n2. Received systemic maintenance immunosuppressive therapy for GVHD other than listed in the inclusion criteria within one week prior to first IMP administration\n3. Received any systemic or topical cyclosporin within one week prior to first IMP administration and/or during the clinical trial\n4. Received mechanical ventilation\n5. Pregnant or breast feeding woman\n6. Has known hypersensitivity to cyclosporin A\n7. Has a serum creatinine value of more than 3 mg/dL\n8. Unlikely to comply with visits, inhalation procedures or spirometric measurements scheduled in the protocol\n9. Receipt of an investigational drug as part of a clinical trial within four weeks prior to first administration of IMP\n10.  Any co-existing medical condition that in the investigator\u0092s judgement will substantially increase the risk associated with the subject's participation in the study\n11.  Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures\n12. Has been previously enrolled in this study", "patientInfoSheet": "Not available in web format, please use the contact details below to request a patient information sheet", "recruitmentStart": "2010-03-01T00:00:00.000Z", "recruitmentEnd": "2012-12-01T00:00:00.000Z", "recruitmentStatusOverride": "Stopped"}, "conditions": {"condition": {"description": "Bronchiolitis obliterans", "diseaseClass1": "Respiratory", "diseaseClass2": "Other chronic obstructive pulmonary disease"}}, "interventions": {"intervention": {"description": "This trial was stopped as of 31/03/2010.\n\nSubjects will be randomised (1:1:1) to one of three treatment arms: \n1. 1 x 10 mg/day L-CsA and 1 x placebo/day \n2. 2 x 10 mg/day L-CsA \n3. 2 x placebo \n\nSubjects will be stratified according to several baseline risk factors, e.g. myeloablative versus non-myeloablative regimen. Treatment duration will be 12 weeks with a 36 week follow-up period. After successful completion of the study, the patient may enter the follow-up clinical trial (ref: 12011.203) after fulfilling in/exclusion criteria.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Phase II", "drugNames": "Liposomal cyclosporin A (L-CsA)"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder17940-0", "contactId": "Contact55923_17940", "sponsorId": "Sponsor54487"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact55923_17940", "title": "Ms", "forename": "Stefanie", "surname": "Prante", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Clinical Trial Manager\nPARI Pharma GmbH\nSteinerstrasse 15A", "city": "Munich", "country": "Germany", "zip": "81369", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor54487", "organisation": "PARI Pharma GmbH (Germany)", "website": "http://www.paripharma.com", "sponsorType": "Industry", "contactDetails": {"address": "Steinerstrasse 15A", "city": "Munich", "country": "Germany", "zip": "81369", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.476581.9", "rorId": "https://ror.org/011pcrd91"}, "funder": {"@id": "Funder17940-0", "name": "PARI Pharma GmbH (Germany)", "fundRef": null}}, {"trial": {"@lastUpdated": "2010-03-31T00:00:00.000Z", "@version": "20", "isrctn": {"@dateAssigned": "2005-07-05T00:00:00.000Z", "#text": "03397663"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Evaluation of the efficacy and safety of a Sheabutter extract on cold sores (herpes simplex labialis)", "scientificTitle": null, "acronym": null, "studyHypothesis": "The hypothesis is that various concentrations of Sheabutter extract BSP110 are able to reduce the healing time of cold sores and prevent their recurrence in participants with 6 or more self reported cold sores a year.", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Acute study: Duration of initial herpes labialis episode.\nMaintenance study: Number of herpes labialis episodes during the 6 months of the maintenance study period.", "secondaryOutcome": "Acute study:\n1. Investigator-assessment of Herpes Lesion development stage\n2. Participant self-assessment of severity of symptoms including pain, tingling, itching, swelling, blistering, oozing and crusting using Likert scales (0 = none, 1 = mild, 2 = moderate, 3 = severe)\n3. Quality of Life measured by Short Form-36 questionnaire and the Dermatology Life Quality Index\n\nMaintenance study:\n1. The number of participants who develop lesions during the 6 months of the maintenance study period\n2. Time to first herpes episode\n3. Duration of lesions\n4. Use of rescue medication\n5. Participant self-assessment of severity of symptoms including pain, tingling, itching, swelling, blistering, oozing and crusting using Likert scales (0 = none, 1 = mild, 2 = moderate, 3 = severe)\n6. Quality of Life measured by Short Form-36 questionnaire and the Dermatology Life Quality Index", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN03397663", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "BPCS01"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Treatment"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2005-02-01T00:00:00.000Z", "overallEndDate": "2006-03-31T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Australia"}, "trialCentres": {"trialCentre": {"@id": "16b5bfb2-d5e4-4911-90ff-4becee131739", "name": "Mater Health Services", "address": null, "city": "South Brisbane", "state": null, "country": "Australia", "zip": "4101"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Subjects aged 18 and 75 years, in good general health who have a clinical history of recurrent herpes labialis, with at least six self reported episodes of herpes lesion in the past year and at least one recurrance every three months.", "ageRange": "Adult", "lowerAgeLimit": {"@unit": "Years", "@value": "18.0"}, "gender": "Both", "targetEnrolment": "160", "totalFinalEnrolment": null, "totalTarget": "160", "exclusion": "1. History of immunodeficiency\n2. Use of other antiviral agents (including herbal medications), anti-inflammatory medications, steroids or analgesics during the treatment period\n3. Known allergy to Sheabutter\n4. Liver function tests greater than 3 times the upper limit of normal at baseline\n5. Female participants who are lactating, pregnant or planning to become pregnant\n6. Participants who have participated in another clinical trial in the last 30 days\n7. Participants unwilling to comply with the study protocol\n8. Any other condition, which in the opinion of the investigators could compromise the study", "patientInfoSheet": null, "recruitmentStart": "2005-02-01T00:00:00.000Z", "recruitmentEnd": "2006-03-31T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Herpes Simplex Labialis", "diseaseClass1": "Skin and Connective Tissue Diseases", "diseaseClass2": "Herpes simplex labialis"}}, "interventions": {"intervention": {"description": "Acute study - 100% sheabutter extract BSP 110 ointment versus placebo of yellow petrolatum.\nMaintenance study - 25% sheabutter lip balm versus 25% yellow petrolatum lip balm.", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Sheabutter extract"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": null, "publicationStage": null, "biomedRelated": "false", "basicReport": null, "plainEnglishReport": null}, "outputs": null, "parties": {"funderId": "Funder13056-0", "contactId": "Contact50589_13056", "sponsorId": "Sponsor48971"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact50589_13056", "title": "Dr", "forename": "Phillip", "surname": "Cheras", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Mater Health Services\n2nd Floor, Community Health Services Bldg\n39 Annerley Rd", "city": "South Brisbane", "country": "Australia", "zip": "4101", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected"}, "sponsor": {"@id": "Sponsor48971", "organisation": "BSP Pharma A/S (Denmark)", "website": null, "sponsorType": "Industry", "contactDetails": {"address": "M.P Bruuns Gade 27", "city": "Aarhus", "country": "Denmark", "zip": "DK-8000", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions"}}, "privacy": "Protected", "gridId": "grid.420009.f", "rorId": "https://ror.org/05tzrdd39"}, "funder": {"@id": "Funder13056-0", "name": "BSP Pharma A/S (Denmark) - AUD478,790", "fundRef": null}}, {"trial": {"@lastUpdated": "2010-03-31T00:00:00.000Z", "@version": "23", "isrctn": {"@dateAssigned": "2003-11-24T00:00:00.000Z", "#text": "32866390"}, "trialDescription": {"@thirdPartyFilesAcknowledgement": "false", "acknowledgment": "true", "title": "Prevention by epidural Injection of postherpetic Neuralgia in the Elderly", "scientificTitle": null, "acronym": "PINE", "studyHypothesis": "Not provided at time of registration", "plainEnglishSummary": "Not provided at time of registration", "primaryOutcome": "Not provided at time of registration", "secondaryOutcome": "Not provided at time of registration", "trialWebsite": null, "ethicsApprovalRequired": "Old ethics approval format", "ethicsCommittees": null, "ethicsApproval": "Not provided at time of registration"}, "externalRefs": {"doi": "10.1186/ISRCTN32866390", "eudraCTNumber": null, "irasNumber": null, "clinicalTrialsGovNumber": null, "protocolSerialNumber": "NWO 945-02-009"}, "trialDesign": {"studyDesign": "Randomised controlled trial", "primaryStudyDesign": "Interventional", "secondaryStudyDesign": "Randomised controlled trial", "trialSettings": {"trialSetting": "Not specified"}, "trialTypes": {"trialType": "Prevention"}, "overallStatusOverride": null, "reasonAbandoned": null, "overallStartDate": "2004-01-01T00:00:00.000Z", "overallEndDate": "2005-01-01T00:00:00.000Z"}, "participants": {"recruitmentCountries": {"country": "Netherlands"}, "trialCentres": {"trialCentre": {"@id": "951fc5a0-1546-4141-96c2-ca80e01f6f22", "name": "Julius Center for Health Sciences and Primary Care", "address": null, "city": "Utrecht", "state": null, "country": "Netherlands", "zip": "3500 AB"}}, "participantTypes": {"participantType": "Patient"}, "inclusion": "Elderly patients (age >50 years) with acute herpes zoster (skin lesions <7 days) below dermatome C6 in primary care", "ageRange": "Not Specified", "gender": "Not Specified", "targetEnrolment": "550", "totalFinalEnrolment": null, "totalTarget": "550", "exclusion": "Not provided at time of registration", "patientInfoSheet": null, "recruitmentStart": "2004-01-01T00:00:00.000Z", "recruitmentEnd": "2005-01-01T00:00:00.000Z", "recruitmentStatusOverride": null}, "conditions": {"condition": {"description": "Herpes zoster/postherpetic neuralgia", "diseaseClass1": "Infections and Infestations", "diseaseClass2": "Herpes"}}, "interventions": {"intervention": {"description": "Index group: Standard treatment (antiviral and analgesic medication) plus epidural injection of local anaesthetics and corticosteroids.\n  \nControl group: Standard treatment (antiviral and analgesic medication)", "interventionType": "Drug", "pharmaceuticalStudyTypes": null, "phase": "Not Specified", "drugNames": "Methylprednisolone-acetate, bupivacaine"}}, "results": {"publicationPlan": "Not provided at time of registration", "ipdSharingStatement": null, "dataPolicies": {"dataPolicy": "Not provided at time of registration"}, "publicationDetails": "2004 Protocol article in https://pubmed.ncbi.nlm.nih.gov/15005813 Protocol\n2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16427490 Results", "publicationStage": "Results", "biomedRelated": "true", "basicReport": null, "plainEnglishReport": null}, "outputs": {"output": [{"@id": "7fbc9994-50e7-479e-be0d-1505cb934bc8", "@outputType": "protocolarticle", "@artefactType": "ExternalLink", "@dateCreated": "2004-01-26T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "https://pubmed.ncbi.nlm.nih.gov/15005813"}, "description": "Protocol", "productionNotes": null}, {"@id": "dc1c9d73-5692-4bf7-9bc0-109d5b7ecb6e", "@outputType": "resultsarticle", "@artefactType": "ExternalLink", "@dateCreated": "2006-01-21T00:00:00.000Z", "@dateUploaded": "", "@peerReviewed": "true", "@patientFacing": "false", "@createdBy": "Data migration", "externalLink": {"@url": "https://pubmed.ncbi.nlm.nih.gov/16427490"}, "description": "Results", "productionNotes": null}]}, "parties": {"funderId": "Funder5719-0", "contactId": "Contact7150_5719", "sponsorId": "Sponsor5313"}, "miscellaneous": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "ipdSharingPlan": "No"}, "attachedFiles": null}, "contact": {"@id": "Contact7150_5719", "title": "Prof", "forename": "Theo", "surname": "Verheij", "orcid": null, "contactTypes": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "contactType": "Scientific"}, "contactDetails": {"address": "Julius Center for Health Sciences and Primary Care\nUniversity Medical Center\nPO Box 85060", "city": "Utrecht", "country": "Netherlands", "zip": "3500 AB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)30 253 8188"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "T.J.M.Verheij@med.uu.nl"}}, "privacy": "Public"}, "sponsor": {"@id": "Sponsor5313", "organisation": "Julius Center for Health Sciences and Primary Care (The Netherlands)", "website": null, "sponsorType": "Hospital/treatment centre", "contactDetails": {"address": "University Medical Center\nUtrecht\nPO Box 85060", "city": "Utrecht", "country": "Netherlands", "zip": "3500 AB", "telephone": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "+31 (0)30 253 8788"}, "email": {"@xmlns:ssb": "http://www.67bricks.com/isrctn/functions", "#text": "w.opstelten@med.uu.nl"}}, "privacy": "Public", "gridId": "grid.7692.a", "rorId": "https://ror.org/0575yy874"}, "funder": {"@id": "Funder5719-0", "name": "The Netherlands Organisation for Scientific Research (The Netherlands) (ref: 945-02-009)", "fundRef": null}}]}}